Jehonathan H. Pinthus, MD, PhD, FRCSC

Jehonathan H. Pinthus, MD, PhD, FRCSC

McMaster University

Hamilton, ON, Canada

Jehonathan Pinthus MD, PhD is an Associate Professor in the Department of Surgery Division of Urology McMaster University. He is a surgical oncologist-Urologist who completed his MD at the Hebrew University in Jerusalem Israel and his Urology training at the Sheba Medical Centre Tel Aviv University Israel. He then completed 2.5 years of SUO- accredited fellowship in Uro-Oncology in the University of Toronto. Dr. Pinthus earned his PhD at the Weizmann Institute of Science working on gene immunotherapy of prostate cancer.

He is heading a basic and translational research laboratory at McMaster University and his research interests relates to the patients individual host factors and metabolism that affects prostate cancer growth and response to therapy. Dr. Pinthus published more than 80 peer reviewed papers, several book chapters and is a member of the editorial board of European Urology and Prostate Cancer and Prostatic Disease journals. Dr. Pinthus is the principle investigator on many distinguished research grants the most recent one is a $3.5 M Movember-Prostate Cancer Canada grant titled ” Role of androgen deprivation therapy in cardiovascular disease – a longitudinal prostate cancer study (RADICAL PC)” to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease.

Articles by Jehonathan H. Pinthus, MD, PhD, FRCSC

ADT Impact on Cardiovascular Health

These downloadable slides by Dr. Jehonathan H. Pinthus, MD, FRCSC are on the topic of the impact of ADT treatment on the cardiovascular health of patients. These slides were presented at a satellite symposium presented in conjunction with the AUA Annual Meeting held on Sunday, May 14, 2017 entitled “Navigating the Adverse Effects of ADT: Improving Patient Outcomes”. Download...

Read More

Treatment of Invasive Bladder Cancer in the Elderly and Frail Patient

Dr. Jehonathan Pinthus presented “Treatment of Invasive Bladder Cancer in the Elderly and Frail Patient ” at the  International Bladder Cancer Update meeting on Tuesday, January 24, 2017.     Keywords: bladder cancer, BCG, CIS, chemotherapy, cystectomy, elderly, invasive, neoadjuvant, nonagenarians, TURBT How to cite: Pinthus, Jehonathan. “Treatment of Invasive Bladder Cancer in the Elderly and Frail Patient ” January 24, 2017. Accessed Dec 2017. https://grandroundsinurology.com/treatment-invasive-bladder-cancer-elderly-frail-patient   Transcript Treatment of Invasive Bladder Cancer in the Elderly and Frail Patient I think this is a very contemporary topic because we are living in an aging society. If you look here, and you know if you really want to...

Read More

Thromboembolic Complications in Bladder Cancer

Dr. Jehonathan Pinthus presented “Thromboembolic Complications in Bladder Cancer” at the  International Bladder Cancer Update meeting on Tuesday, January 24, 2017.     Keywords: bladder cancer, chemotherapy, cystectomy, neoadjuvant, prophylaxis, thromboembolic, VTE How to cite: Pinthus, Jehonathan. “Thromboembolic Complications in Bladder Cancer” January 24, 2017. Accessed Dec 2017. https://grandroundsinurology.com/thromboembolic-complications-bladder-cancer   Transcript Thromboembolic Complications in Bladder Cancer   I would like to take you through three trajectories of the disease, one is in the post or peri-radical cystectomy, and time. The other one it’s a different patient population, which I think deserves specific attentions, and those are the patients who receive neoadjuvant cisplatin-based chemotherapy. And finally, a...

Read More

Neuroendocrine Prostate Cancer (NEPC)

Dr. Jehonathan Pinthus presented “Neuroendocrine Prostate Cancer (NEPC)” at the 27th annual International Prostate Cancer Update meeting on Thursday, January 26, 2017.     Keywords: prostate cancer, adenocarcinoma, androgen, castration-resistant, kinase, neuroendocrine How to cite: Pinthus, Jehonathan. “Neuroendocrine Prostate Cancer (NEPC)” January 26, 2017. Accessed Dec 2017. https://grandroundsinurology.com/neuroendocrine-prostate-cancer-nepc   Transcript Neuroendocrine Prostate Cancer (NEPC)   Neuroendocrine cells are actually part of the normal prostate. You can detect them in the benign prostate as well if you do the right staining. This is with chromogranin and synaptophysin. They’re probably part of the normal, they are part of the normal architecture of the prostate, they...

Read More

Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation?

Dr. Jehonathan Pinthus presented at the 26th International Prostate Cancer Update on Friday, January 22, 2016 on “Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation?”.   Keywords: neuroendrocine prostate cancer,  ADT, adenocarcinoma, phenotype, AURKA Kinase How to cite: Pinthus, Jehonathan.”Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation.” Grand Rounds in Urology. January 22, 2016. Dec 2017. https://grandroundsinurology.com/prostate-cancer-jehonathan-pinthus-neuroendocrine-prostate-cancer/. Trancript Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation? I was asked by Dr. Crawford to also deliver a talk about the neuroendocrine differentiation in prostate cancer patients...

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -